Patisiran Sodium
drugOn this page
Also known as Onpattro
Summary
Patisiran Sodium (CHEMBL4297536) is an approved oligonucleotide; indicated across 4 conditions including polyneuropathy and amyloidosis.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Oligonucleotide
- Indications: 4 conditions
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297536 |
| Name | Patisiran Sodium |
| Type | Oligonucleotide |
| Max phase | 4 |
Also known as: Onpattro, Patisiran sodium, PATISIRAN SODIUM
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
4 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| polyneuropathy | 4 | MONDO:0001824 | EFO:0009562 |
| amyloidosis | 4 | MONDO:0019065 | EFO:1001875 |
| familial amyloid neuropathy | 4 | MONDO:0007100 | EFO:0004129 |
| hereditary amyloidosis | 4 | MONDO:0018634 | MONDO:0018634 |
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).